A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-BAFF receptor CAR T cell therapy (Primary)
Indications B-cell leukaemia; B-cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; First in man
Sponsors PeproMene Bio

08 Feb 2024 Planned End Date changed from 18 Nov 2026 to 18 Nov 2027.
08 Feb 2024 Planned primary completion date changed from 18 Nov 2025 to 18 Nov 2026.
18 Jan 2024 According to a PeproMene Bio media release, company announced that the cohort 1 first patient treated in its Phase 1 relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) clinical trial of PMB-CT01 (BAFFR-CAR T Cells) has reached complete remission at one-month post treatment.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com